WMS Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

WMS Partners’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,254	Closed	-$32K	–	218
2017 Q2	$32K	Hold	3,254	–	–	﹤0.01%	211
2017 Q1	$79K	Hold	3,254	–	–	0.01%	198
2016 Q4	$104K	Hold	3,254	–	–	0.01%	185
2016 Q3	$163K	Buy	+3,254	New	+$135K	0.02%	187
2016 Q2	–	Sell	-3,254	Closed	-$214K	–	225
2016 Q1	$214K	Hold	3,254	–	–	0.03%	186
2015 Q4	$202K	Hold	3,254	–	–	0.03%	193
2015 Q3	$218K	Hold	3,254	–	–	0.03%	186
2015 Q2	$317K	Hold	3,254	–	–	0.04%	219
2015 Q1	$304K	Hold	3,254	–	–	0.04%	213
2014 Q4	$289K	Hold	3,254	–	–	0.04%	170
2014 Q3	$225K	Hold	3,254	–	–	0.04%	218
2014 Q2	$187K	Hold	3,254	–	–	0.03%	235
2014 Q1	$129K	Hold	3,254	–	–	0.02%	236
2013 Q4	$136K	Hold	3,254	–	–	0.02%	226
2013 Q3	$97K	Hold	3,254	–	–	0.02%	201
2013 Q2	$173K	Buy	+3,254	New	+$143K	0.03%	223

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

WMS Partners's MACK Position: Q3 2017 in Review

WMS Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 3,254 shares — an estimated $32K sold.

WMS Partners first reported a position in MACK in Q2 2013 and held it in 16 quarters. The position peaked at $317K in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

WMS Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
WMS Partners sold 3,254 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $32K.
WMS Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 16 quarters.
WMS Partners's Merrimack Pharmaceuticals, Inc. position peaked at $317K in Q2 2015.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on WMS Partners's 13F filing for Q3 2017, filed 27 Oct 2017.